Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial
Purpose
This phase III trial compares less intense hormone therapy and radiation therapy to usual hormone therapy and radiation therapy in treating patients with high risk prostate cancer and low gene risk score. This trial also compares more intense hormone therapy and radiation therapy to usual hormone therapy and radiation therapy in patients with high risk prostate cancer and high gene risk score. Apalutamide may help fight prostate cancer by blocking the use of androgen by the tumor cells. Radiation therapy uses high energy rays to kill tumor cells and shrink tumors. Giving a shorter hormone therapy treatment may work the same at controlling prostate cancer compared to the usual 24 month hormone therapy treatment in patients with low gene risk score. Adding apalutamide to the usual treatment may increase the length of time without prostate cancer spreading as compared to the usual treatment in patients with high gene risk score.
Conditions
- Metastatic Malignant Neoplasm in the Bone
- Prostate Adenocarcinoma
- Stage III Prostate Cancer AJCC v8
- Stage IIIA Prostate Cancer AJCC v8
- Stage IIIB Prostate Cancer AJCC v8
- Stage IIIC Prostate Cancer AJCC v8
- Stage IVA Prostate Cancer AJCC v8
Eligibility
- Eligible Ages
- Over 18 Years
- Eligible Genders
- Male
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- PRIOR TO STEP 1 REGISTRATION - Pathologically proven diagnosis of adenocarcinoma of prostate cancer within 180 days prior to registration - High-risk disease defined as having at least one or more of the following: - PSA > 20 ng/mL prior to starting ADT Note: Patients receiving a 5-alpha reductase inhibitor (ex. finasteride) at the time of enrollment are eligible. The baseline PSA value should be doubled for PSAs taken while on 5-alpha reductase inhibitors and the medication should be discontinued prior to randomization but a washout period is not required. - cT3a-T4 by digital exam or imaging (American Joint Committee on Cancer [AJCC] 8th edition [Ed.]) - Gleason score of 8-10 - Node positive by conventional imaging with a short axis of at least 1.0 cm - Appropriate stage for study entry based on the following diagnostic workup: - History/physical examination within 120 days prior to registration; - Bone imaging within 120 days prior to registration; - Note: To be eligible, patient must have no definitive evidence of bone metastases (M0) on bone scan or sodium fluoride (NaF) PET within 120 days prior to registration (negative NaF PET/CT or negative Axumin or choline PET or negative fluciclovine, choline or prostate-specific membrane antigen (PSMA) PET within 120 days prior to registration is an acceptable substitute if they have been performed). Patients who have bone metastases established only fluciclovine, choline, or PSMA PET but not definitive on bone scan or NaF PET will still be eligible - CT or MRI of the pelvis within 120 days prior to registration (negative fluciclovine, choline, or PSMA PET within 120 days prior to registration is an acceptable substitute). As with bone staging, nodal staging for trial purposes will be based off of conventional imaging findings only - Patients with confirmed N1 metastases on conventional imaging (CT/MRI) as defined by ≥10 mm on short axis are eligible but will be automatically assigned to the intensification study. Patients who are positive by fluciclovine, choline, or PSMA PET (i.e. N1), but whose nodes do not meet traditional size criteria for positivity (i.e. they measure ≥ 10 mm on either the CT or MRI portion of the PET or on a dedicated CT or MRI) will not be considered N1 for the trial and will not automatically be assigned to the intensification study - Age ≥ 18 - Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 within 120 days prior to registration - Hemoglobin ≥ 9.0 g/dL, independent of transfusion and/or growth factors (within 120 days prior to registration) - Platelet count ≥ -100 x 10^3/uL independent of transfusion and/or growth factors (within 120 days prior to registration) - Creatinine clearance (CrCl) ≥ 30 mL/min estimated by Cockcroft-Gault equation (within 120 days prior to registration) - For Black patients whose renal function is not considered adequate by Cockcroft-Gault formula, an alternative formula that takes race into account (Chronic Kidney Disease Epidemiology Collaboration CKD-EPI formula) may be used for calculating creatinine clearance for trial eligibility - Either a CrCl ≥ 30 ml/min or calculated glomerular filtration rate (GFR) ≥ 30 will make a patient eligible - Total bilirubin =< 1.5 x institutional upper limit of normal (ULN) (within 120 days prior to registration) - Note: In subjects with Gilbert's syndrome, if total bilirubin is > 1.5 x ULN, measure direct and indirect bilirubin and if direct bilirubin is ≤ 1.5 x ULN, subject is eligible - Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT]) or alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) ≤ 2.5 x institutional ULN (within 120 days prior to registration) - Serum albumin ≥ 3.0 g/dL (within 120 days prior to registration) - The patient must agree to use a condom (even men with vasectomies) and another effective method of birth control if he is having sex with a woman of childbearing potential or agree to use a condom if he is having sex with a woman who is pregnant while on study drug and for 3 months following the last dose of study drug - Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial and have a CD4 count ≥ 200 cells/microliter within 60 days prior to registration. Note: HIV testing is not required for eligibility for this protocol. Of note, for patients with HIV in the intensification trial randomized to apalutamide, highly active antiretroviral therapy (HAART) may need to be adjusted to medications that do not interact with apalutamide - For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable after or on suppressive therapy within 60 days prior to registration, if indicated. Note: HBV viral testing is not required for eligibility for this protocol - Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial. Note: Any patient with a cancer (other than keratinocyte carcinoma or carcinoma in situ or low-grade non-muscle invasive bladder cancer) who has been disease-free for less than 3 years must contact the principal investigator - The patient or a legally authorized representative must provide study-specific informed consent prior to study entry - PRIOR TO STEP 2 RANDOMIZATION - Confirmation of Decipher score - Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load within 60 days prior. Note: Apalutamide may interfere with HCV drugs. Patients on HCV medications should alert their infectious diseases physician if they get randomized to apalutamide due to the possibility that apalutamide can affect the bioavailability of some HCV medications. HCV viral testing is not required for eligibility for this protocol - For patients entering the Intensification Cohort ONLY: Patients must discontinue or substitute concomitant medications known to lower the seizure threshold at least 30 days prior to Step 2 randomization
Exclusion Criteria
- PRIOR TO STEP 1 REGISTRATION: - Definitive radiologic evidence of metastatic disease outside of the pelvic nodes (M1a, M1b or M1c) on conventional imaging (i.e. bone scan, CT scan, MRI) - Prior systemic chemotherapy within ≤ 3 years prior to registration; note that prior chemotherapy for a different cancer is allowed (completed > 3 years prior to registration - Prior radical prostatectomy - Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields - Current use of 5-alpha reductase inhibitor. NOTE: If the alpha reductase inhibitor is stopped prior to randomization the patient is eligible - History of any of the following: - Seizure disorder - Current severe or unstable angina - New York Heart Association Functional Classification III/IV (Note: Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification.) - History of any condition that in the opinion of the investigator, would preclude participation in this study - Evidence of any of the following at registration: - Active uncontrolled infection requiring IV antibiotics - Baseline severe hepatic impairment (Child Pugh Class C) - Inability to swallow oral pills - Any current condition that in the opinion of the investigator, would preclude participation in this study - Prior pharmacologic androgen ablation for prostate cancer is allowed only if the onset of androgen ablation (both luteinizing hormone-releasing hormone [LHRH] agonist and oral anti-androgen) is ≤ 60 days prior to registration; Please note: baseline PSA must be obtained prior to the start of any ADT - PRIOR TO STEP 2 RANDOMIZATION: - Evidence of known gastrointestinal disorder affecting absorption of oral medications at registration - For patients entering the Intensification Cohort ONLY: Presence of uncontrolled hypertension (persistent systolic blood pressure [BP] ≥ 160 mmHg or diastolic BP ≥ 100 mmHg). Subjects with a history of hypertension are allowed, provided that BP is controlled to within these limits by anti-hypertensive treatment
Study Design
- Phase
- Phase 3
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel Assignment
- Primary Purpose
- Treatment
- Masking
- None (Open Label)
Arm Groups
Arm | Description | Assigned Intervention |
---|---|---|
Active Comparator Arm I (de-intensification study) |
Patients undergo RT over 2-11 weeks and receive ADT (consisting of either leuprolide, goserelin, triptorelin, degarelix, buserelin or histrelin and bicalutamide or flutamide) for 24 months in the absence of disease progression or unacceptable toxicity. |
|
Experimental Arm II (de-intensification study) |
Patients undergo RT over 2-11 weeks and receive ADT (consisting of either leuprolide, goserelin, triptorelin, degarelix, buserelin or histrelin and bicalutamide or flutamide) for 12 months in the absence of disease progression or unacceptable toxicity. |
|
Active Comparator Arm III (intensification study) |
Patients undergo RT over 2-11 weeks and receive ADT as in Arm I. |
|
Experimental Arm IV (intensification study) |
Patients undergo RT over 2-11 weeks and receive ADT (consisting of either leuprolide, goserelin, triptorelin, degarelix, buserelin or histrelin) for 24 months in the absence of disease progression or unacceptable toxicity. Patients also receive apalutamide PO QD. Treatment repeats every 90 days for up to 8 cycles (24 months) in the absence of disease progression or unacceptable toxicity. |
|
Recruiting Locations
Fairbanks, Alaska 99701
Gilbert, Arizona 85297
Site Public Contact
480-922-4600
Peoria, Arizona 85381
Site Public Contact
623-773-2873
Scottsdale, Arizona 85258
Site Public Contact
480-922-4600
Tucson, Arizona 85719
Little Rock, Arkansas 72205
Site Public Contact
501-686-8274
Auburn, California 95603
Bakersfield, California 93301
Site Public Contact
661-323-4673
Duarte, California 91010
Dublin, California 94568
Site Public Contact
877-642-4691
Fremont, California 94538
Fremont, California 94538
Site Public Contact
510-745-6433
Fresno, California 93720
Greenbrae, California 94904
Site Public Contact
415-925-7325
Irvine, California 92618
Site Public Contact
877-467-3411
La Jolla, California 92093
Lancaster, California 93534
Los Angeles, California 90048
Site Public Contact
310-423-8965
Marysville, California 95901
Site Public Contact
530-749-4400
Modesto, California 95355
Modesto, California 95356
Napa, California 94558
Site Public Contact
707-521-3830
Oakland, California 94611
Orange, California 92868
Site Public Contact
714-734-6220
Orange, California 92868
Palo Alto, California 94304
Roseville, California 95661
Roseville, California 95661
Sacramento, California 95814
Sacramento, California 95816
Sacramento, California 95817
Site Public Contact
916-734-3089
Sacramento, California 95823
San Francisco, California 94115
San Francisco, California 94158
San Jose, California 95119
San Jose, California 95124
San Leandro, California 94577
San Mateo, California 94402
Santa Barbara, California 93105
Santa Clara, California 95051
Santa Rosa, California 95403
South Pasadena, California 91030
South San Francisco, California 94080
Tarzana, California 91356
Site Public Contact
818-981-3818
Torrance, California 90505
Torrance, California 90509
Site Public Contact
310-517-4665
Truckee, California 96161
Site Public Contact
530-582-6450
Upland, California 91786
Vallejo, California 94589
Walnut Creek, California 94596
Walnut Creek, California 94598
Site Public Contact
925-941-4246
Aurora, Colorado 80045
Site Public Contact
720-848-0650
Boulder, Colorado 80304
Colorado Springs, Colorado 80909
Site Public Contact
719-365-2406
Colorado Springs, Colorado 80920
Site Public Contact
719-364-6700
Edwards, Colorado 81632
Site Public Contact
970-569-7429
Fort Collins, Colorado 80524
Site Public Contact
970-297-6150
Fort Collins, Colorado 80528
Greeley, Colorado 80631
Greeley, Colorado 80631
Highlands Ranch, Colorado 80129
Site Public Contact
720-848-0650
Loveland, Colorado 80538
Site Public Contact
970-203-7083
Loveland, Colorado 80539
Bridgeport, Connecticut 06606
Site Public Contact
860-972-4700
Derby, Connecticut 06418
Fairfield, Connecticut 06824
Greenwich, Connecticut 06830
Guilford, Connecticut 06437
Hartford, Connecticut 06102
Site Public Contact
860-545-5363
Hartford, Connecticut 06105
Meriden, Connecticut 06451
Site Public Contact
866-662-5678
New Britain, Connecticut 06050
Site Public Contact
860-224-5660
New Haven, Connecticut 06520
North Haven, Connecticut 06473
Orange, Connecticut 06477
Stamford, Connecticut 06902
Stamford, Connecticut 06904
Site Public Contact
203-323-8944
Trumbull, Connecticut 06611
Waterford, Connecticut 06385
Dover, Delaware 19901
Newark, Delaware 19713
Newark, Delaware 19713
Boca Raton, Florida 33486
Site Public Contact
561-955-4800
Gainesville, Florida 32610
Miami, Florida 33176
Site Public Contact
786-596-2000
Plantation, Florida 33324
Tampa, Florida 33606
Atlanta, Georgia 30303
Site Public Contact
404-489-9164
Atlanta, Georgia 30308
Atlanta, Georgia 30308
Site Public Contact
888-946-7447
Atlanta, Georgia 30322
Site Public Contact
404-778-1868
Atlanta, Georgia 30342
Site Public Contact
404-851-7115
Savannah, Georgia 31405
Aurora, Illinois 60504
Barrington, Illinois 60010
Site Public Contact
847-842-4847
Bloomington, Illinois 61704
Canton, Illinois 61520
Carthage, Illinois 62321
Chicago, Illinois 60611
Chicago, Illinois 60612
Chicago, Illinois 60612
Site Public Contact
312-355-3046
Chicago, Illinois 60637
Chicago, Illinois 60657
Site Public Contact
773-296-5360
Crystal Lake, Illinois 60014
Danville, Illinois 61832
Decatur, Illinois 62526
DeKalb, Illinois 60115
Downers Grove, Illinois 60515
Effingham, Illinois 62401
Elgin, Illinois 60123
Site Public Contact
847-429-2907
Elmhurst, Illinois 60126
Eureka, Illinois 61530
Galesburg, Illinois 61401
Geneva, Illinois 60134
Hazel Crest, Illinois 60429
Site Public Contact
708-799-9995
Kewanee, Illinois 61443
Lake Forest, Illinois 60045
Libertyville, Illinois 60048
Libertyville, Illinois 60048
Macomb, Illinois 61455
Mattoon, Illinois 61938
Maywood, Illinois 60153
Site Public Contact
708-226-4357
Naperville, Illinois 60540
Site Public Contact
630-646-6075
New Lenox, Illinois 60451
Oak Lawn, Illinois 60453-2699
Site Public Contact
800-323-8622
Orland Park, Illinois 60462
Ottawa, Illinois 61350
Park Ridge, Illinois 60068
Site Public Contact
847-384-3621
Pekin, Illinois 61554
Peoria, Illinois 61615
Peoria, Illinois 61636
Peoria, Illinois 61637
Peru, Illinois 61354
Princeton, Illinois 61356
Rockford, Illinois 61114
Shiloh, Illinois 62269
Springfield, Illinois 62781
Urbana, Illinois 61801
Warrenville, Illinois 60555
Washington, Illinois 61571
Cedar Rapids, Iowa 52402
Cedar Rapids, Iowa 52403
Site Public Contact
319-365-4673
Cedar Rapids, Iowa 52403
Site Public Contact
319-363-2690
Des Moines, Iowa 50309
Site Public Contact
515-241-6727
Des Moines, Iowa 50309
Site Public Contact
515-241-3305
Des Moines, Iowa 50314
Site Public Contact
515-282-2200
Kansas City, Kansas 66160
Olathe, Kansas 66061
Overland Park, Kansas 66210
Salina, Kansas 67401
Topeka, Kansas 66606
Site Public Contact
785-295-8000
Westwood, Kansas 66205
Wichita, Kansas 67214
Lexington, Kentucky 40509
Metairie, Louisiana 70006
New Orleans, Louisiana 70112
Bath, Maine 04530
Portland, Maine 04102
Site Public Contact
207-885-7565
Rockport, Maine 04856
Sanford, Maine 04073
Site Public Contact
207-459-1600
Scarborough, Maine 04074
South Portland, Maine 04106
Annapolis, Maryland 21401
Baltimore, Maryland 21201
Baltimore, Maryland 21201
Site Public Contact
800-888-8823
Baltimore, Maryland 21287
Bel Air, Maryland 21014
Site Public Contact
443-643-3010
Bethesda, Maryland 20814
Easton, Maryland 21601
Boston, Massachusetts 02114
Site Public Contact
877-726-5130
Boston, Massachusetts 02215
Site Public Contact
877-442-3324
Milford, Massachusetts 01757
Site Public Contact
877-332-4294
South Weymouth, Massachusetts 02190
Site Public Contact
781-624-5000
Ann Arbor, Michigan 48106
Ann Arbor, Michigan 48109
Site Public Contact
800-865-1125
Bay City, Michigan 48706
Brighton, Michigan 48114
Brighton, Michigan 48114
Brighton, Michigan 48116
Site Public Contact
800-865-1125
Canton, Michigan 48188
Canton, Michigan 48188
Chelsea, Michigan 48118
Chelsea, Michigan 48118
Clarkston, Michigan 48346
Clarkston, Michigan 48346
Clinton Township, Michigan 48038
Dearborn, Michigan 48124
Site Public Contact
248-551-7695
Detroit, Michigan 48201
Detroit, Michigan 48202
Farmington Hills, Michigan 48334
Farmington Hills, Michigan 48334
Flint, Michigan 48532
Grand Rapids, Michigan 49503
Grand Rapids, Michigan 49503
Kalamazoo, Michigan 49007
Kalamazoo, Michigan 49007
Lansing, Michigan 48910
Lansing, Michigan 48912
Site Public Contact
517-364-9400
Lapeer, Michigan 48446
Livonia, Michigan 48154
Macomb, Michigan 48044
Madison Heights, Michigan 48071
Mount Clemens, Michigan 48043
Port Huron, Michigan 48060
Royal Oak, Michigan 48073
Site Public Contact
248-551-7695
Saginaw, Michigan 48601
Saint Joseph, Michigan 49085
Traverse City, Michigan 49684
Troy, Michigan 48085
Site Public Contact
248-551-7695
Troy, Michigan 48098
West Bloomfield, Michigan 48322
Wyoming, Michigan 49519
Ypsilanti, Michigan 48197
Coon Rapids, Minnesota 55433
Duluth, Minnesota 55805
Minneapolis, Minnesota 55407
Minneapolis, Minnesota 55415
Monticello, Minnesota 55362
Rochester, Minnesota 55905
Site Public Contact
855-776-0015
Saint Louis Park, Minnesota 55416
Saint Paul, Minnesota 55101
Jackson, Mississippi 39216
Site Public Contact
601-815-6700
Cape Girardeau, Missouri 63703
Columbia, Missouri 65212
Site Public Contact
573-882-7440
Creve Coeur, Missouri 63141
Joplin, Missouri 64804
Kansas City, Missouri 64154
Lee's Summit, Missouri 64064
North Kansas City, Missouri 64116
Rolla, Missouri 65401
Saint Louis, Missouri 63110
Saint Louis, Missouri 63129
Saint Louis, Missouri 63131
Site Public Contact
314-996-5569
Saint Louis, Missouri 63136
Saint Peters, Missouri 63376
Springfield, Missouri 65804
Site Public Contact
417-269-4520
Billings, Montana 59101
Great Falls, Montana 59405
Bellevue, Nebraska 68123
Omaha, Nebraska 68118
Site Public Contact
402-559-5600
Omaha, Nebraska 68198
Concord, New Hampshire 03301
Site Public Contact
603-224-2556
Exeter, New Hampshire 03833
Site Public Contact
800-439-3837
Lebanon, New Hampshire 03756
Manchester, New Hampshire 03103
Site Public Contact
800-339-6484
Camden, New Jersey 08103
Site Public Contact
856-325-6757
Egg Harbor Township, New Jersey 08234
Site Public Contact
609-748-7200
Hamilton, New Jersey 08690
Site Public Contact
609-631-6946
Livingston, New Jersey 07039
New Brunswick, New Jersey 08903
Site Public Contact
732-235-7356
Newark, New Jersey 07101
Site Public Contact
732-235-7356
Paramus, New Jersey 07652
Site Public Contact
201-634-5792
Ridgewood, New Jersey 07450
Somerville, New Jersey 08876
Toms River, New Jersey 08755
Voorhees, New Jersey 08043
Site Public Contact
856-325-6757
Albuquerque, New Mexico 87102
Albuquerque, New Mexico 87102
Albuquerque, New Mexico 87110
Rio Rancho, New Mexico 87124
Bay Shore, New York 11706
Site Public Contact
516-734-8896
Brooklyn, New York 11215
Buffalo, New York 14263
Flushing, New York 11355
Forest Hills, New York 11375
Site Public Contact
718-520-6620
Glens Falls, New York 12801
Site Public Contact
518-926-6700
Lake Success, New York 11042
Site Public Contact
516-734-8896
New York, New York 10021
Site Public Contact
516-734-8896
New York, New York 10032
New York, New York 10065
Site Public Contact
212-434-4460
New York, New York 10065
Site Public Contact
212-746-1848
Rego Park, New York 11374
Site Public Contact
718-312-3446
Rochester, New York 14642
Site Public Contact
585-275-5830
Sleepy Hollow, New York 10591
Site Public Contact
914-366-1600
Stony Brook, New York 11794
Site Public Contact
800-862-2215
Syracuse, New York 13210
Site Public Contact
315-464-5476
Valhalla, New York 10595
Webster, New York 14580
Charlotte, North Carolina 28203
Site Public Contact
800-804-9376
Charlotte, North Carolina 28204
Charlotte, North Carolina 28210
Site Public Contact
980-442-2000
Charlotte, North Carolina 28262
Site Public Contact
800-804-9376
Charlotte, North Carolina 28277
Site Public Contact
800-804-9376
Concord, North Carolina 28025
Site Public Contact
800-804-9376
Durham, North Carolina 27705
Durham, North Carolina 27710
Site Public Contact
888-275-3853
Huntersville, North Carolina 28078
Matthews, North Carolina 28105
Monroe, North Carolina 28112
Site Public Contact
980-442-2000
Mooresville, North Carolina 28117
Raleigh, North Carolina 27607
Raleigh, North Carolina 27609
Site Public Contact
919-862-5400
Raleigh, North Carolina 27614
Supply, North Carolina 28462
Site Public Contact
910-754-4716
Wilmington, North Carolina 28401
Site Public Contact
910-251-1839
Wilmington, North Carolina 28401
Site Public Contact
910-342-3000
Winston-Salem, North Carolina 27103
Winston-Salem, North Carolina 27157
Site Public Contact
336-713-6771
Grand Forks, North Dakota 58201
Site Public Contact
701-780-6520
Akron, Ohio 44304
Akron, Ohio 44307
Barberton, Ohio 44203
Columbus, Ohio 43210
Medina, Ohio 44256
Sylvania, Ohio 43560
Oklahoma City, Oklahoma 73104
Gresham, Oregon 97030
Site Public Contact
503-413-2150
Portland, Oregon 97210
Tualatin, Oregon 97062
Site Public Contact
503-413-1742
Allentown, Pennsylvania 18104
Site Public Contact
610-776-4714
Altoona, Pennsylvania 16601
Beaver, Pennsylvania 15009
Bethlehem, Pennsylvania 18015
Site Public Contact
484-503-4151
Broomall, Pennsylvania 19008
Carlisle, Pennsylvania 17015
Chadds Ford, Pennsylvania 19317
Chambersburg, Pennsylvania 17201
Danville, Pennsylvania 17822
Drexel Hill, Pennsylvania 19026
Easton, Pennsylvania 18045
Ephrata, Pennsylvania 17522
Site Public Contact
717-721-4840
Erie, Pennsylvania 16505
Erie, Pennsylvania 16544
Site Public Contact
814-452-5000
Farrell, Pennsylvania 16121
Gettysburg, Pennsylvania 17325
Site Public Contact
877-441-7957
Glen Mills, Pennsylvania 19342
Site Public Contact
610-284-8237
Greensburg, Pennsylvania 15601
Site Public Contact
724-838-1900
Harrisburg, Pennsylvania 17109
Hershey, Pennsylvania 17033-0850
Indiana, Pennsylvania 15701
Jefferson Hills, Pennsylvania 15025
Johnstown, Pennsylvania 15901
Site Public Contact
814-534-4724
Lebanon, Pennsylvania 17042
Lewisburg, Pennsylvania 17837
Meadville, Pennsylvania 16335
Mechanicsburg, Pennsylvania 17050
Monroeville, Pennsylvania 15146
Site Public Contact
412-858-7746
Monroeville, Pennsylvania 15146
Moon, Pennsylvania 15108
Philadelphia, Pennsylvania 19107
Philadelphia, Pennsylvania 19140
Site Public Contact
215-728-2983
Pittsburgh, Pennsylvania 15212
Site Public Contact
877-284-2000
Pittsburgh, Pennsylvania 15213
Site Public Contact
412-647-2811
Pittsburgh, Pennsylvania 15215
Site Public Contact
412-784-4900
Pittsburgh, Pennsylvania 15224
Site Public Contact
412-578-5000
Pittsburgh, Pennsylvania 15232
Site Public Contact
412-647-8073
Pittsburgh, Pennsylvania 15232
Site Public Contact
412-621-2334
Pittsburgh, Pennsylvania 15237
Site Public Contact
412-367-6454
Pittsburgh, Pennsylvania 15243
Site Public Contact
412-502-3920
Pottsville, Pennsylvania 17901
Quakertown, Pennsylvania 18951
Site Public Contact
610-776-4714
Quakertown, Pennsylvania 18951
Site Public Contact
610-776-4714
Seneca, Pennsylvania 16346
Site Public Contact
814-676-7900
Stroudsburg, Pennsylvania 18360
Uniontown, Pennsylvania 15401
Uniontown, Pennsylvania 15401
Site Public Contact
724-437-2503
Washington, Pennsylvania 15301
Washington, Pennsylvania 15301
West Chester, Pennsylvania 19380
Site Public Contact
610-431-5297
West Reading, Pennsylvania 19611
Site Public Contact
610-988-9323
Wexford, Pennsylvania 15090
Wilkes-Barre, Pennsylvania 18711
Williamsport, Pennsylvania 17754
York, Pennsylvania 17403
Site Public Contact
877-441-7957
York, Pennsylvania 17408
Site Public Contact
717-724-6760
Providence, Rhode Island 02903
Site Public Contact
401-444-1488
Westerly, Rhode Island 02891
Bluffton, South Carolina 29910
Charleston, South Carolina 29425
Greenville, South Carolina 29601
Greenville, South Carolina 29607
Greenwood, South Carolina 29646
Greer, South Carolina 29651
Spartanburg, South Carolina 29303
Baytown, Texas 77521
Houston, Texas 77030
Site Public Contact
713-790-2700
Houston, Texas 77070
Nassau Bay, Texas 77058
San Antonio, Texas 78229
Sugar Land, Texas 77479
Site Public Contact
281-242-2873
The Woodlands, Texas 77385
American Fork, Utah 84003
Farmington, Utah 84025
Logan, Utah 84321
Murray, Utah 84107
Ogden, Utah 84403
Provo, Utah 84604
Riverton, Utah 84065
Saint George, Utah 84770
Salt Lake City, Utah 84106
Salt Lake City, Utah 84106
Salt Lake City, Utah 84112
Salt Lake City, Utah 84143
Berlin, Vermont 05602
Site Public Contact
802-225-5400
Burlington, Vermont 05401
Saint Johnsbury, Vermont 05819
Alexandria, Virginia 22304
Fairfax, Virginia 22031
Fairfax, Virginia 22033
Midlothian, Virginia 23114
Richmond, Virginia 23230
Richmond, Virginia 23298
Roanoke, Virginia 24014
Seattle, Washington 98101
Vancouver, Washington 98684
Vancouver, Washington 98686
Site Public Contact
503-413-2150
Wheeling, West Virginia 26003
Site Public Contact
304-243-6442
Antigo, Wisconsin 54409
Appleton, Wisconsin 54911
Appleton, Wisconsin 54915
Ashland, Wisconsin 54806
Brookfield, Wisconsin 53045
Burlington, Wisconsin 53105
Chilton, Wisconsin 53014
Eau Claire, Wisconsin 54701
Franklin, Wisconsin 53132
Germantown, Wisconsin 53022
Grafton, Wisconsin 53024
Green Bay, Wisconsin 54301
Green Bay, Wisconsin 54303
Green Bay, Wisconsin 54311
Kenosha, Wisconsin 53142
La Crosse, Wisconsin 54601
Site Public Contact
855-776-0015
Marinette, Wisconsin 54143
Menomonee Falls, Wisconsin 53051
Site Public Contact
262-257-5100
Mequon, Wisconsin 53097
Milwaukee, Wisconsin 53209
Milwaukee, Wisconsin 53211
Milwaukee, Wisconsin 53215
Milwaukee, Wisconsin 53226
Site Public Contact
414-805-3666
Milwaukee, Wisconsin 53233
Milwaukee, Wisconsin 53295
Site Public Contact
888-469-6614
Oak Creek, Wisconsin 53154
Site Public Contact
414-805-0505
Oshkosh, Wisconsin 54904
Oshkosh, Wisconsin 54904
Racine, Wisconsin 53405
Racine, Wisconsin 53406
Rhinelander, Wisconsin 54501
Sheboygan, Wisconsin 53081
Sheboygan, Wisconsin 53081
Stevens Point, Wisconsin 54481
Sturgeon Bay, Wisconsin 54235-1495
Summit, Wisconsin 53066
Two Rivers, Wisconsin 54241
Wausau, Wisconsin 54401
Site Public Contact
877-405-6866
Wauwatosa, Wisconsin 53226
Wauwatosa, Wisconsin 53226
West Allis, Wisconsin 53227
West Bend, Wisconsin 53095
Site Public Contact
414-805-0505
Wisconsin Rapids, Wisconsin 54494
Site Public Contact
715-422-7718
More Details
- NCT ID
- NCT04513717
- Status
- Recruiting
- Sponsor
- NRG Oncology
Detailed Description
PRIMARY OBJECTIVES: I. To determine whether men with National Comprehensive Cancer Network (NCCN) high risk prostate cancer who are in the lower 2/3 of Decipher genomic risk (=< 0.85) can be treated with 12 months androgen deprivation therapy (ADT) plus radiation therapy (RT) instead of 24 months ADT+RT and experience non-inferior metastasis-free survival. (De-intensification study) II. To determine whether men with NCCN high risk prostate cancer who are in the upper 1/3 of Decipher genomic risk (> 0.85) or have node-positive disease by conventional imaging (magnetic resonance imaging [MRI] or computed tomography [CT] scan) will have a superior metastasis-free survival (MFS) through treatment intensification with apalutamide added to the standard of RT plus 24 month ADT. (Intensification study) SECONDARY OBJECTIVES: I. To compare overall survival (OS) between the standard of care (RT plus 24 months of ADT) and either the de-intensification (RT plus 12 months of ADT) or intensification arm (RT plus 24 months of ADT plus apalutamide). (De-intensification and intensification studies) II. To compare time to prostate specific antigen (PSA) failure or start of salvage treatment between the standard of care (RT plus 24 months of ADT) and either the de-intensification arm (RT plus 12 months of ADT) or intensification arm (RT plus 24 months of ADT plus apalutamide). (De-intensification and intensification studies) III. To compare PSA failure-free survival with non-castrate testosterone and no additional therapies between the standard of care (RT plus 24 months of ADT) and either the de-intensification arm (RT plus 12 months of ADT) or intensification arm (RT plus 24 months of ADT plus apalutamide). (De-intensification and intensification studies) IV. To compare MFS judged based on either standard or molecular imaging between the standard of care (RT plus 24 months of ADT) and either the de-intensification arm (RT plus 12 months of ADT) or intensification arm (RT plus 24 months of ADT plus apalutamide). (De-intensification and intensification studies) V. To compare prostate cancer-specific mortality between the standard of care (RT plus 24 months of ADT) and either the de-intensification arm (RT plus 12 months of ADT) or intensification arm (RT plus 24 months of ADT plus apalutamide). (De-intensification and intensification studies) VI. To compare testosterone levels at the time of PSA failure and metastases between the standard of care (RT plus 24 months of ADT) and either the de-intensification arm (RT plus 12 months of ADT) or intensification arm (RT plus 24 months of ADT plus apalutamide). (De-intensification and intensification studies) VII. To compare time to testosterone recovery (defined as a T > 200) between the standard of care (RT plus 24 months of ADT) and either the de-intensification arm (RT plus 12 months of ADT) or intensification arm (RT plus 24 months of ADT plus apalutamide). (De-intensification and intensification studies) VIII. To compare adverse events, both clinician-reported using Common Terminology Criteria for Adverse Events (CTCAE) version (v) 5.0 and patient-reported using Patient Reported Outcome (PRO)-CTCAE items, between the standard of care (RT plus 24 months of ADT) and either the de-intensification arm (RT plus 12 months of ADT) or intensification arm (RT plus 24 months of ADT plus apalutamide). (De-intensification and intensification studies) EXPLORATORY OBJECTIVES: I. To compare changes in cardio-metabolic markers, including body mass index, and waist circumference, between the standard of care (RT plus 24 months of ADT) and either the de-intensification arm (RT plus 12 months of ADT) or intensification arm (RT plus 24 months of ADT plus apalutamide). (De-intensification and intensification studies) II. To determine a machine learning/artificial intelligence algorithm for radiotherapy quality assurance. (De-intensification and Intensification studies) III. To perform future translational correlative studies using biological and imaging data. (De-intensification and intensification studies) IV. Impact of PET use in high-risk prostate cancer PATIENT-REPORTED OUTCOMES OBJECTIVES: PRIMARY OBJECTIVES: I. To compare sexual and hormonal function related quality of life, as measured by the Expanded Prostate Cancer Index Composite-26 (EPIC), between the standard of care (RT plus 24 months of ADT) and the de-intensification arm (RT plus 12 months of ADT). (De-Intensification Study) II. To compare fatigue, as measured by the Patient Reported Outcomes Measurement Information System (PROMIS)-Fatigue instrument, between the standard of care (RT plus 24 months of ADT) and the intensification arm (RT plus 24 months of ADT plus apalutamide). (Intensification Study) SECONDARY OBJECTIVES: I. To compare depression, as measured by the PROMIS-depression, between the standard of care (RT plus 24 months of ADT) and the de-intensification arm (RT plus 12 months of ADT). (De-Intensification Study) II. To compare depression, as measured by the PROMIS-depression, between the standard of care (RT plus 24 months of ADT) and the intensification arm (RT plus 24 months of ADT plus apalutamide). (Intensification Study) EXPLORATORY OBJECTIVES: I. To compare cognition, as measured by the Functional Assessment of Chronic Illness Therapy-Cognitive (FACT-Cog) perceived cognitive abilities subscale, between the standard of care (RT plus 24 months of ADT) and the de-intensification arm (RT plus 12 months of ADT). (De-Intensification Study) II. To compare bowel and urinary function related quality of life, as measured by the Expanded Prostate Cancer Index Composite-26 (EPIC), between the standard of care (RT plus 24 months of ADT) and the de-intensification arm (RT plus 12 months of ADT). (De-Intensification Study) III. To compare fatigue, as measured by the PROMIS-Fatigue instrument, between the standard of care (RT plus 24 months of ADT) and the de-intensification arm (RT plus 12 months of ADT). (De-Intensification Study) IV. To compare sexual and hormonal function related quality of life, as measured by the Expanded Prostate Cancer Index Composite-26 (EPIC), between the standard of care (RT plus 24 months of ADT) and the intensification arm (RT plus 24 months of ADT plus apalutamide). (Intensification Study) V. To compare bowel and urinary function related quality of life, as measured by the Expanded Prostate Cancer Index Composite-26 (EPIC), between the standard of care (RT plus 24 months of ADT) and the intensification arm (RT plus 24 months of ADT plus apalutamide). (Intensification Study) VI. To compare cognition, as measured by the Functional Assessment of Chronic Illness Therapy-Cognitive (FACT-Cog) perceived cognitive abilities subscale, between the standard of care (RT plus 24 months of ADT) and the intensification arm (RT plus 24 months of ADT plus apalutamide). (Intensification Study) OUTLINE: Patients are randomized to 1 of 4 arms. DE-INTENSIFICATION STUDY (DECIPHER SCORE =< 0.85): ARM I: Patients undergo radiation therapy (RT) over 2-11 weeks and receive ADT (consisting of either leuprolide, goserelin, triptorelin, degarelix, buserelin or histrelin and bicalutamide or flutamide) for 24 months in the absence of disease progression or unacceptable toxicity. ARM II: Patients undergo RT over 2-11 weeks and receive ADT (consisting of either leuprolide, goserelin, triptorelin, degarelix, buserelin or histrelin and bicalutamide or flutamide) for 12 months in the absence of disease progression or unacceptable toxicity. INTENSIFICATION STUDY (DECIPHER SCORE > 0.85 OR NODE POSITIVE): ARM III: Patients undergo RT over 2-11 weeks and receive ADT (consisting of either leuprolide, goserelin, triptorelin, degarelix, buserelin or histrelin and bicalutamide or flutamide) for 24 months in the absence of disease progression or unacceptable toxicity. ARM IV: Patients undergo RT over 2-11 weeks and receive ADT (consisting of either leuprolide, goserelin, triptorelin, degarelix, buserelin or histrelin) for 24 months in the absence of disease progression or unacceptable toxicity. Patients also receive apalutamide orally (PO) once daily (QD). Treatment repeats every 90 days for up to 8 cycles (24 months) in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up annually.